Phase II Study of IMRT With SIB as Adjuvant Treatment for High Risk Resected Well-differentiated Thyroid Cancer.

Phase 2

Completed

• Conditions: Thyroid Neoplasms

• Registration Number: NCT00279721
• Lead Sponsor: Alberta Health services

Brief Summary

Resected well-differentiated thyroid neoplasms with at least one high risk feature will receive adjuvant radiation using IMRT with SIB. The acute toxicity and locoregional control rate at 2 years will be recorded.

Detailed Description

Resected well-differentiated thyroid neoplasms with at least one high risk feature will receive adjuvant radiation using IMRT with SIB. The acute toxicity and locoregional control rate at 2 years will be recorded.

Study Timeline

• Study Start: 2006-01
• Study First Submitted: 2006-01-18
• Study First Submitted QC: 2006-01-18
• Study First Posted: 2006-01-20
• Primary Completion: 2010-06
• Study Completion: 2010-06
• Status Verified: 2011-07
• Last Update Submitted: 2012-01-18
• Last Update Posted: 2012-01-19

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

• resected well-differentiated throid cancer with at least one high risk feature for locoregional recurrence

Exclusion Criteria

• medullary or anaplastic thyroid cancer, unresectable

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Primary Outcome Measures

Name	Time	Method
toxicity according to RTOG criteria
locoregional control